Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$14.65 USD
+0.47 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Deciphera Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -194.94 | -178.93 | -299.96 | -266.49 | -192.26 |
Depreciation/Amortization & Depletion | 2.10 | 2.95 | 3.01 | 2.31 | 0.83 |
Net Change from Assets/Liabilities | -1.54 | -31.65 | 0.82 | -13.85 | 25.72 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 47.68 | 54.77 | 55.31 | 38.35 | 16.41 |
Net Cash From Operating Activities | -146.70 | -152.86 | -240.82 | -239.68 | -149.30 |
Property & Equipment | -0.78 | -0.84 | -1.97 | -5.31 | -4.94 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 13.33 | -33.47 | 182.82 | 33.77 | -455.59 |
Other Investing Activities | 0.00 | 0.00 | -4.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 12.55 | -34.31 | 176.85 | 28.46 | -460.52 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 152.64 | 165.42 | 14.93 | 227.62 | 438.29 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -1.29 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.63 | -0.43 | -0.04 | -0.82 | -0.62 |
Net Cash from Financing Activities | 152.00 | 164.99 | 14.89 | 226.80 | 436.37 |
Effect of Exchange Rate Changes | 0.91 | -0.15 | 0.25 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 18.77 | -22.32 | -48.83 | 15.58 | -173.44 |
Cash at Beginning of Period | 64.74 | 87.06 | 135.90 | 120.32 | 293.76 |
Cash at End of Period | 83.51 | 64.74 | 87.06 | 135.90 | 120.32 |
Diluted Net EPS | -2.29 | -2.37 | -5.16 | -4.78 | -4.48 |
Fiscal Year End for Deciphera Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -194.94 | -147.75 | -98.17 | -49.61 |
Depreciation/Amortization & Depletion | NA | 2.10 | 1.64 | 1.18 | 0.61 |
Net Change from Assets/Liabilities | NA | -1.54 | -6.10 | -15.16 | -12.50 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 47.68 | 34.32 | 24.07 | 12.05 |
Net Cash From Operating Activities | NA | -146.70 | -117.89 | -88.08 | -49.46 |
Property & Equipment | NA | -0.78 | -0.72 | -0.65 | -0.36 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 13.33 | 11.07 | -30.40 | -35.05 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 12.55 | 10.35 | -31.05 | -35.41 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 152.64 | 151.75 | 136.16 | 135.32 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.63 | -0.63 | -0.63 | -0.63 |
Net Cash from Financing Activities | NA | 152.00 | 151.11 | 135.52 | 134.69 |
Effect of Exchange Rate Changes | NA | 0.91 | -0.23 | 0.26 | 0.08 |
Net Change In Cash & Equivalents | NA | 18.77 | 43.35 | 16.65 | 49.90 |
Cash at Beginning of Period | NA | 64.74 | 64.74 | 64.74 | 64.74 |
Cash at End of Period | NA | 83.51 | 108.09 | 81.39 | 114.64 |
Diluted Net EPS | NA | -0.54 | -0.58 | -0.57 | -0.60 |